Register and share your invite link to earn from video plays and referrals.

Search results for HERS【お願い】誌面の内容掲載はお控えいただけますようお願いいたします🙇‍♀️
HERS【お願い】誌面の内容掲載はお控えいただけますようお願いいたします🙇‍♀️ community
One keyword maps to one global community path.
Create community
People
Not Found
Tweets including HERS【お願い】誌面の内容掲載はお控えいただけますようお願いいたします🙇‍♀️
$HIMS & HERS Q3’26 EARNINGS HIGHLIGHTS 🔹 Revenue: $890.4M (Est. $893M) 🔴; +49% YoY 🔹 EPS: -$0.14 (Est. $0.06) 🔴 🔹 Adj. EBITDA: $82.4M (Est. $85.1M) 🔴; +5% YoY 🔹 Gross Margin: 57%; -1,700 bps YoY Customers & Assets: 🔹 Subscribers: 2,788; +13% YoY 🔹 Monthly Revenue per Subscriber: $105; +30% YoY FY26 Guide: 🔹 Revenue: $3.13B-$3.15B (Est. $3.21B) 🔴 🔹 Adj. EBITDA: $257M-$277M (Est. $295M) 🔴 🔹 Adj. EBITDA Margin: 8%-9% Q4 Guide: 🔹 Revenue: $875M-$895M (Est. $953M) 🔴 🔹 Adj. EBITDA: $70M-$90M (Est. $107M) 🔴 🔹 Adj. EBITDA Margin: 8%-10% Other Q3 Metrics: 🔹 Operating Cash Flow: $65.4M 🔹 Free Cash Flow: $26.0M Segment Net Revenue: 🔹 United States: $657.1M; +21% YoY 🔹 Rest of World: $233.3M; +321% YoY Key Updates: 🔹 Restructuring Charges: $3.8M included in Adjusted EBITDA reconciliation Comments: 🔸 “Revenue grew 49% year-over-year, our second consecutive quarter of acceleration, with domestic revenue up 21% year-over-year and international revenue up more than 300% year-over-year.” 🔸 “We delivered those results while intentionally pacing marketing spend ahead of several planned expansions to our platform in the fourth quarter, which we expect will set us up well heading into 2027.”
Show more
Hims & Hers CEO Andrew Dudum on CNBC: * Says biggest lever from AI is adherence, as 10-15% of patients on heart disease medicine stay on past 12 months. It's the #1# killer for fathers, and it costs $0.02-0.03 to compound. Sees path for adherence to 2-3x * Data loop closure via hardware that he says is around 12 months away. One ecosystem that has at-home scales, $30 blood tests, wearables, Dexcom GCM, and bluetooth pill bottle * Compounding enabled GLP1s to price down 80-90% within a year when they launched $150-200/mo against branded at $1,500. Expects $40-50/mo type pricing by 2030 or so when semaglutide goes off patent * Says foundational models without closed-loop data set is not that valuable, in his opinion. Had been building around Sierra for the last year but in-house outperformed very quickly once launched. Costs can be 70-80% less with open-weight models * His dad was 38 and had stage 4 colon cancer, and the $20,000 test now costs $30 which is something Hims will bundle that they'll offer "very shortly" * Will do a peptides launch with a few guardrails including US supply, doctor dosage, and blood tests every 3-6 months * Also gave his own regimen, which is interesting Bookmark and worth a watch:
Show more
Julie has got hers, have you got yours? #BeThere# in the 2026/27 Season and buy your #buryfc# Season Ticket 👇
Hannah bumps into an old friend of hers at Whole Foods. "So, Judith, how’s life been treating you?" asks Hannah. "Well Hannah, if you must know," replies Judith, "my very best friend has run off with my husband. I haven’t seen him now for over a week." "Oh Judith," says Hannah, "I’m so sorry to hear it. Who is this kurveh? Do I know her?" "No, I’ve absolutely no idea who she is," replies Judith. "But you just called her your best friend," says Hannah, looking puzzled." "Listen Hannah, anyone who takes that shmendrick of a husband away from me will always be my very best friend."
Show more
Feel Every Vibe: Connect Your Toy to Hers 📲🔌 👉
Hims & Hers Health: Don't Nitpick Quarterly Results $HIMS #trading# #business# #finance#
LA voters criticize Karen Bass' policies without knowing they're hers: 'A Band-Aid on the problem'
JUST IN: Hims & Hers officially enters Australia by rebranding Eucalyptus Pilot as Hims.
HIMS & HERS HEALTH $HIMS ENTERS AUSTRALIA The telehealth company says the launch marks its first market presence in the Asia-Pacific region.
JUST IN: Hims & Hers CEO reveals Bluetooth medicine bottles that know “if people took their pills” are about 12 months away.